IGG4 Orbitopathy

Witten By Prof. Khalil Al-Salem

IgG4-related disease is an increasingly recognized immune-mediated condition that can affect multiple organs. However, orbital involvement is one of its most striking presentations. IgG4 orbitopathy often presents with ocular proptosis, eyelid swelling, and lacrimal gland enlargement. Although these findings may resemble other orbital diseases, the underlying process is unique. Therefore, early recognition is essential. One of the most remarkable features is the good steroid response, which often leads to rapid clinical improvement. However, some patients may relapse or require additional therapy. In addition, newer treatments such as Rituximab have significantly improved outcomes. In this article, we will explore IgG4-related disease with special focus on IgG4 orbitopathy, and we will discuss treatment options such as steroids and Rituximab.

Pathophysiology of IgG4-Related Disease

The exact cause of IgG4-related disease remains unclear. However, immune dysregulation plays a central role. There is activation of B cells and T helper cells. Consequently, IgG4-producing plasma cells accumulate in affected tissues. In addition, cytokines promote fibrosis and tissue remodeling. Although IgG4 is usually considered anti-inflammatory, it contributes to disease progression. Therefore, the condition combines inflmmation and fibrosis.

Orbital Involvement in IgG4 Disease

IgG4 orbitopathy involves several orbital structures. The lacrimal gland is most commonly affected. However, extraocular muscles and orbital fat may also be involved. In addition, the infraorbital nerve is frequently enlarged.
This pattern helps distinguish the disease from other orbital conditions. Although it may resemble thyroid eye disease, key differences exist. Therefore, careful evaluation is required.

Clinical Presentation

Patients with IgG4 orbitopathy often present with ocular proptosis. This proptosis is usually painless and slowly progressive. However, it may become cosmetically significant over time. Eyelid swelling is another common feature. It is often bilateral, although unilateral cases occur. In addition, lacrimal gland enlargement produces fullness in the upper eyelid. Diplopia may develop if extraocular muscles are involved. Consequently, patients may experience restricted eye movement. However, vision is usually preserved unless complications occur.
Dry eye symptoms are also common. This occurs due to lacrimal gland dysfunction. Despite these symptoms, severe pain is typically absent.

Radiological Features

Imaging plays an important role in diagnosis. CT and MRI often show bilateral lacrimal gland enlargement. In addition, extraocular muscles may be enlarged. Unlike thyroid eye disease, tendon involvement may be present. Therefore, this finding can be helpful diagnostically. In addition, infraorbital nerve enlargement is highly suggestive. Diffuse orbital infiltration may also be seen. However, imaging alone cannot confirm the diagnosis.

Diagnosis

Definitive diagnosis requires histopathological confirmation. Biopsy typically shows lymphoplasmacytic infiltration and storiform fibrosis. In addition, obliterative phlebitis may be present. Immunostaining demonstrates increased IgG4-positive plasma cells. Although serum IgG4 levels are often elevated, they are not always reliable. Therefore, normal levels do not exclude the disease. A combination of clinical, radiological, and histological findings is essential. However, biopsy remains the gold standard.

Differential Diagnosis

Several conditions may mimic IgG4 orbitopathy. These include thyroid eye disease and orbital lymphoma. In addition, sarcoidosis and idiopathic orbital inflammation must be considered. Although clinical features may overlap, certain findings help differentiation. For example, infraorbital nerve enlargement favors IgG4 disease. Therefore, careful assessment is critical.

Treatment

Corticosteroids remain the first-line treatment. One of the defining features is a good steroid response. Patients often improve rapidly after starting therapy. Proptosis, swelling, and diplopia typically decrease. However, relapse may occur if steroids are tapered quickly. Therefore, gradual tapering is recommended. Despite the good steroid response, long-term use has side effects. In addition, some patients become steroid-dependent.

Rituximab Therapy

Rituximab is an important treatment option. It is particularly useful in refractory or relapsing cases. In addition, it helps reduce steroid dependence. Rituximab targets CD20-positive B cells. Consequently, it reduces IgG4 production and inflammation. Many patients show significant improvement after treatment. Although effective, it should be used carefully. Monitoring is required due to potential side effects. However, it has transformed the management of severe disease.

Prognosis

The prognosis of IgG4 orbitopathy is generally favorable. Most patients respond well to treatment. However, early diagnosis is essential. Delayed treatment may lead to fibrosis. Consequently, structural damage may become irreversible. Therefore, prompt management is critical.

Conclusion

IgG4-related disease is an important systemic condition with significant orbital involvement. IgG4 orbitopathy commonly presents with ocular proptosis and lacrimal gland enlargement. Although it mimics other diseases, it shows a good steroid response. In addition, Rituximab provides an effective option for resistant cases. Therefore, early recognition and treatment are essential.